Hereditary/Acquired Bleeding Disorders

A final analysis of phase 3b STASEY study data found continued benefit and no new safety concerns with use of emicizumab (Hemlibra) in adult and adolescent hemophilia A patients with inhibition of factor VIII, according to a press release from Genentech. Emicizumab, a bispecific factor IXa- and factor X-directed antibody that restores the blood clotting process in hemophilia A, continued to demonstrate effective control of bleeding; 82.6% of participants had no bleeding episodes requiring treatment. Also, annualized bleeding rates were consistent with data from the pivotal HAVEN studies. There were no new cases of thrombotic microangiopathy or serious thrombotic events related to emicizumab. A total of 18.1% of participants had an emicizumab-related AE, with injection site reaction being the most common (9.8%).